Meloxicam Injection B.P. (Vet)

Meloxicam Injection B.P. (Vet) is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.


Meloxicam Injection B.P. (Vet) is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.


Dosage and Administration:

Carefully consider the potential benefits and risk of Meloxicam and other treatment options before deciding to use Meloxicam. Use the lowest effective dose for the shortest duration consistent with individual response.


Dogs: Meloxicam Injection should be administered initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by Meloxicam Oral Suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.



Dogs with known hypersensitivity to meloxicam should not receive Meloxicam Injection.



Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For IV or SQ injectable use in dogs. All dogs should undergo a thorough history and physical examination before administering any NSAID. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to, and periodically during use of any NSAID in dogs.


Owner should be advised to observe their dogs for signs of potential drug toxicity.



The safe use of Meloxicam Injection in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. Safety has not been established for intramuscular (IM) administration in dogs. When administering Meloxicam Injection, use a syringe of appropriate size to ensure precise dosing. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease that has not been previously diagnosed.


There are no reviews yet.

Be the first to review “Meloxicam Injection B.P. (Vet)”

Your email address will not be published. Required fields are marked *